Overview

Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

Status:
Not yet recruiting

Trial end date:
2026-10-31

Target enrollment:

Participant gender:

Summary

To learn if giving immune checkpoint therapy (such as atezolizumab and bevacizumab) to patients who have HCC and are receiving DAAs may help to control HCC and hepatitis C.

Phase:

Phase 4

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

National Cancer Institute (NCI)

Treatments:

Atezolizumab
Bevacizumab
Ribavirin
Sofosbuvir
Velpatasvir